Effectiveness of Azathioprine for Multiple Sclerosis in Morocco
Author Information
Author(s): Ali Mirhani, Nabila Auajjar, Chouki Slimani, Benaissa Attarassi
Primary Institution: Laboratoire de Biologie et Santé, Faculté des Sciences, Université Ibn-Tofail, Kenitra, Maroc
Hypothesis
The study aims to evaluate the efficacy of azathioprine as a first-line treatment for multiple sclerosis patients who could not access beta-interferons.
Conclusion
The study confirms that azathioprine is beneficial in treating different types of multiple sclerosis in Morocco.
Supporting Evidence
- 82.4% of patients with relapsing-remitting MS were stable or improved after treatment.
- 54.5% of patients with primary progressive MS showed stability or improvement.
- 66.7% of patients with secondary progressive MS were stable or improved.
Takeaway
This study shows that azathioprine can help people with multiple sclerosis feel better, especially those who couldn't get other treatments.
Methodology
A retrospective cohort analysis was conducted on 31 patients with different types of multiple sclerosis who received azathioprine for 2 years, with efficacy assessed using the EDSS score.
Potential Biases
Potential bias due to the retrospective nature of the study and limited generalizability.
Limitations
The study is limited to a specific region in Morocco and only included patients treated with azathioprine without other therapies.
Participant Demographics
Among the 31 patients, 55% had relapsing-remitting MS, 35% had primary progressive MS, and 10% had secondary progressive MS.
Statistical Information
P-Value
0.000 for RRMS, 0.005 for PPMS, 0.1 for SPMS
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website